Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
October 5, 2010
Affibody AB and Amylin Pharmaceuticals, Inc. enter into A License Agreement regarding the Albumod™ platform
Affibody AB and Amylin Pharmaceuticals, Inc. enter into A License Agreement regarding the Albumod™ platform Stockholm, Sweden, October 5, 2010.
Read more
September 3, 2010
Interim Report – January to June 2010
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique...
April 20, 2010
Interim Report – January to March 2010
February 19, 2010
Year-End Report 2009
December 1, 2009
Interim Report – January to September
Interim Report – January to September 2009 Affibody Holding AB (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and...
August 26, 2009
Interim Report – January to June 2009
April 29, 2009
Affibody – Interim Report – January to March 2009
March 24, 2009
Biovitrum gets access to Affibody® Technology
Affibody AB today signed a collaboration agreement with Biovitrum AB (publ) (STO:BVT) with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.
February 23, 2009
Year-End Report 2008
Affibody Holding AB (publ) (“Affibody” or “the Company”) today issued its year-end 2008 report. Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic...
